{"id":471299,"date":"2021-04-06T04:58:17","date_gmt":"2021-04-06T08:58:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=471299"},"modified":"2021-04-06T04:58:17","modified_gmt":"2021-04-06T08:58:17","slug":"ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/","title":{"rendered":"Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc."},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">MILWAUKEE<\/span>, <span class=\"xn-chron\">April 6, 2021<\/span> \/PRNewswire\/ &#8212; Ademi LLP is investigating possible securities fraud claims against Acadia <b>(NASDAQ: ACAD)<\/b>.\u00a0 The investigation results from inaccurate statements Acadia may have made regarding its financial results, business operations and prospects.<\/p>\n<p>Click here to learn more about the investigation: <a href=\"https:\/\/www.ademilaw.com\/case\/acadia-pharmaceuticals-inc\" rel=\"nofollow\">https:\/\/www.ademilaw.com\/case\/acadia-pharmaceuticals-inc<\/a> or call <span class=\"xn-person\">Guri Ademi<\/span> toll-free at 866-264-3995. There is no cost or obligation to you. <\/p>\n<p>The investigation focuses on whether Acadia properly disclosed the facts underlying its supplemental new drug application for NUPLAZID\u00ae (pimavanserin), which is used for the treatment of hallucinations and delusions associated with dementia. \u00a0On <span class=\"xn-chron\">March 8<\/span>, Acadia announced that the FDA had &#8220;identified deficiencies that preclude discussion of labeling and post-marketing requirements\/commitments at this time&#8221; with respect to its NUPLAZID\u00ae application. On <span class=\"xn-chron\">April 5<\/span>, Acadia announced that the FDA had rejected the NUPLAZID\u00ae application because it lacks substantial evidence of effectiveness to support approval.<\/p>\n<p>If you wish to obtain additional information or have information about this investigation, please contact <span class=\"xn-person\">Guri Ademi<\/span> either at <a target=\"_blank\" href=\"mailto:gademi@ademilaw.com\" rel=\"nofollow noopener noreferrer\">gademi@ademilaw.com<\/a> or toll-free: 866-264-3995, <a href=\"https:\/\/www.ademilaw.com\/case\/acadia-pharmaceuticals-inc\" rel=\"nofollow\">https:\/\/www.ademilaw.com\/case\/acadia-pharmaceuticals-inc<\/a>. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>We specialize in securities fraud and shareholder litigation.\u00a0 For more information, please feel free to call us. \u00a0Attorney advertising. Prior results do not guarantee similar outcomes. <\/p>\n<p>Contact:<br \/>Ademi LLP<br \/><span class=\"xn-person\">Guri Ademi<\/span><br \/>3620 East Layton Ave.<br \/><span class=\"xn-location\">Cudahy, WI<\/span> 53110<br \/>Toll Free: (866) 264-3995<br \/>Fax: (414) 482-8001<br \/><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3119696-1&amp;h=3484217420&amp;u=http%3A%2F%2Fwww.ademilaw.com%2F&amp;a=www.ademilaw.com\" rel=\"nofollow noopener noreferrer\">www.ademilaw.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG33056&amp;sd=2021-04-06\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc-301262633.html\">http:\/\/www.prnewswire.com\/news-releases\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc-301262633.html<\/a><\/p>\n<p>SOURCE  Ademi LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CG33056&amp;Transmission_Id=202104060455PR_NEWS_USPR_____CG33056&amp;DateId=20210406\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire MILWAUKEE, April 6, 2021 \/PRNewswire\/ &#8212; Ademi LLP is investigating possible securities fraud claims against Acadia (NASDAQ: ACAD).\u00a0 The investigation results from inaccurate statements Acadia may have made regarding its financial results, business operations and prospects. Click here to learn more about the investigation: https:\/\/www.ademilaw.com\/case\/acadia-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. The investigation focuses on whether Acadia properly disclosed the facts underlying its supplemental new drug application for NUPLAZID\u00ae (pimavanserin), which is used for the treatment of hallucinations and delusions associated with dementia. \u00a0On March 8, Acadia announced that the FDA had &#8220;identified deficiencies that preclude discussion of labeling and post-marketing requirements\/commitments at this time&#8221; with respect to its &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-471299","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire MILWAUKEE, April 6, 2021 \/PRNewswire\/ &#8212; Ademi LLP is investigating possible securities fraud claims against Acadia (NASDAQ: ACAD).\u00a0 The investigation results from inaccurate statements Acadia may have made regarding its financial results, business operations and prospects. Click here to learn more about the investigation: https:\/\/www.ademilaw.com\/case\/acadia-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. The investigation focuses on whether Acadia properly disclosed the facts underlying its supplemental new drug application for NUPLAZID\u00ae (pimavanserin), which is used for the treatment of hallucinations and delusions associated with dementia. \u00a0On March 8, Acadia announced that the FDA had &#8220;identified deficiencies that preclude discussion of labeling and post-marketing requirements\/commitments at this time&#8221; with respect to its &hellip; Continue reading &quot;Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-06T08:58:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG33056&amp;sd=2021-04-06\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc.\",\"datePublished\":\"2021-04-06T08:58:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\\\/\"},\"wordCount\":248,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG33056&amp;sd=2021-04-06\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\\\/\",\"name\":\"Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG33056&amp;sd=2021-04-06\",\"datePublished\":\"2021-04-06T08:58:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG33056&amp;sd=2021-04-06\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG33056&amp;sd=2021-04-06\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/","og_locale":"en_US","og_type":"article","og_title":"Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc. - Market Newsdesk","og_description":"PR Newswire MILWAUKEE, April 6, 2021 \/PRNewswire\/ &#8212; Ademi LLP is investigating possible securities fraud claims against Acadia (NASDAQ: ACAD).\u00a0 The investigation results from inaccurate statements Acadia may have made regarding its financial results, business operations and prospects. Click here to learn more about the investigation: https:\/\/www.ademilaw.com\/case\/acadia-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. The investigation focuses on whether Acadia properly disclosed the facts underlying its supplemental new drug application for NUPLAZID\u00ae (pimavanserin), which is used for the treatment of hallucinations and delusions associated with dementia. \u00a0On March 8, Acadia announced that the FDA had &#8220;identified deficiencies that preclude discussion of labeling and post-marketing requirements\/commitments at this time&#8221; with respect to its &hellip; Continue reading \"Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-06T08:58:17+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG33056&amp;sd=2021-04-06","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc.","datePublished":"2021-04-06T08:58:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/"},"wordCount":248,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG33056&amp;sd=2021-04-06","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/","name":"Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG33056&amp;sd=2021-04-06","datePublished":"2021-04-06T08:58:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG33056&amp;sd=2021-04-06","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG33056&amp;sd=2021-04-06"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-acadia-pharmaceuticals-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=471299"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471299\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=471299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=471299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=471299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}